FDA Approves Complement C5 Inhibitor Zilucoplan for Myasthenia Gravis
With the approval, zilucoplan becomes the first once-daily subcutaneous complement C5 inhibitor available for adults with generalized myasthenia gravis.
United States Samantha Masterson Mjamesf Howard Mjamesf Howard Myasthenia Gravis Foundation Of America Muscular Dystrophy Association
Source: ajmc.com